Ryne Bio
Martin Ostrowski, MS, JD, is Chief Technology Officer at Ryne Bio. Recently as co-Founder of two biotech spin-outs in the advanced medicine sector, he raised over $15MM while leading IP licensing & portfolio development and operations. Martin previously served as Director of Intellectual Property and Business Development at Cellscript, practiced law at Sughrue Mion, PLLC, and led the business development operations at Arteriocyte and Arteriocyte Medical Systems. His professional career has spanned academic research, to business development and commercialization activities, to prosecuting and litigating domestic and international intellectual property, to leadership roles in different biotechnology and pharma-based commercial entities.
This person is not in any teams
This person is not in any offices
Ryne Bio
Ryne Bio is a biotechnology company advancing off-the-shelf neuron replacement therapies as potent disease-modifying treatments for neurological disorders. To achieve this they leverage induced pluripotent stem cell (iPSC) technology, which enables precision manufacture of therapeutically relevant human neurons. Their lead program targeting Parkinson’s Disease is a cryopreserved iPSC dopamine neuron progenitor (RNDP-001) that can be reliably manufactured and delivered